
Cell and Gene Therapy Manufacturing Services Market
Description
Cell and Gene Therapy Manufacturing Services Market
Report Scope:
The scope of this study encompasses an investigation of cell and gene therapy manufacturing services. BCC Research analyzes the manufacturing services based on therapy type, application, disease, and end user. BCC determines the current market status in each segment, examines its impact on future markets, and presents growth forecasts over the next six years. The recent report provides a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections to 2028 and market share for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides the ESG perspective, emerging technologies, and investment outlook.
Report Includes:
34 data tables and 18 additional tables
An overview of the global cell and gene therapy manufacturing services market
Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Highlights of the market potential and quantification of market based on therapy type, application, disease, and end-user
A look into current technologies underlying the market as well as the effects new technologies will have on the market
Coverage of clinical trials pipeline, partnership between pharmaceutical companies, and Contract Development & Manufacturing Organization (CDMO)
Insights into investments from multiple stakeholders, and discussion on increasing focus on personalized medicine for rare and chronic conditions
Information on recent mergers, acquisitions, collaborations, agreements, product launches, and expansions in the market and a relevant patent analysis
Company profiles of major players within the industry, including Catalent, Charles River Laboratories, Lonza, Merck KGaA, and Thermo Fisher Scientific
Table of Contents
138 Pages
- Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Chapter 2 Summary and Highlights
- Market Overview
- Chapter 3 Market Overview and Technology Background
- Overview
- Gene Addition or Augmentation
- Gene Correction
- Gene Silencing
- Manufacturing
- Supply Chain
- Regulatory Landscape
- U.S. (FDA)
- Europe
- Outsourcing of Manufacturing
- Chapter 4 Market Dynamics
- Factors Affecting the Market
- Market Drivers
- Increasing Investment and Funding for CGT Development
- Capacity Expansions for Clinical and Commercial Manufacturing
- Rising Prevalence of Chronic Diseases and Focus on Rare Diseases
- Increasing Strategic Collaborations and Acquisitions
- Market Restraints
- Complex Manufacturing and Supply Chain
- Lack of Skilled Workforce
- Regulatory Hurdles
- Market Opportunities
- Chapter 5 Emerging Technologies
- Introduction
- Emerging Technologies
- Automation
- Digitalization
- Single-Use Technologies
- Emerging Manufacturing Models
- Chapter 6 Market Breakdown by Type
- Overview
- Cell Therapy
- Gene Therapy
- Cell Therapy Types
- Autologous Cell Therapy
- Allogeneic Cell Therapy
- Cell and Gene Therapy Types Based on Vector Type
- Viral Vectors
- Nonviral Vectors
- Chapter 7 Market Breakdown by Application
- Overview
- Clinical Manufacturing
- Commercial Scale Manufacturing
- Chapter 8 Market Breakdown by Disease
- Overview
- Cancer
- Rare Diseases
- Other Diseases
- Chapter 9 Market Breakdown by End User
- Overview
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
- Chapter 10 Market Breakdown by Region
- Overview
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Chapter 11 Sustainability: An ESG Perspective
- Overview
- ESG Practices in the CGT Manufacturing Industry
- Case Studies: Examples of Successful ESG Implementation
- Conclusion
- Chapter 12 M&A, Funding Outlook and Competitive Landscape
- Investments Outlook
- Mergers and Acquisitions
- Strategic Initiatives
- Competitive Analysis
- Chapter 13 Company Profiles
- CATALENT INC.
- CELL AND GENE THERAPY CATAPULT
- CHARLES RIVER LABORATORIES
- FUJIFILM DIOSYNTH BIOTECHNOLOGIES
- LONZA GROUP AG
- MERCK KGAA
- MILTENYI BIOTEC
- NIKON CELL INNOVATION CO. LTD.
- TAKARA BIO INC.
- THERMO FISHER SCIENTIFIC
- WUXI ADVANCED THERAPIES
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.